Screening of Native Valvular Heart Disease Using a Pocket-Sized Transthoracic Echocardiographic Device

John Kikoïne1, Marie Hauguel-Moreau2, Hélène Hergault2

  • 1Department of Cardiology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Centre de référence des cardiomyopathies et des troubles du rythme cardiaque héréditaires ou rares, Université de Versailles-Saint Quentin, Boulogne, France.

Insights

Pocket-sized transthoracic echocardiography (pTTE) shows high sensitivity and specificity for screening valvular heart disease (VHD). This reliable screening tool effectively identifies significant VHD, outperforming traditional auscultation.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Diagnostic Tools

Background:

  • Early diagnosis of valvular heart disease (VHD) is crucial for timely management and therapeutic strategy.
  • Assessing VHD early presents a diagnostic challenge in clinical practice.

Purpose of the Study:

  • To evaluate the performance of pocket-sized transthoracic echocardiography (pTTE) for VHD screening.
  • To compare pTTE against standard transthoracic echocardiography (sTTE) and auscultation for VHD detection.

Main Methods:

  • A study involving 284 unselected patients where sTTE, pTTE, and auscultation were performed by experienced physicians.
  • Standard transthoracic echocardiography (sTTE) served as the gold standard for comparison.
  • Physicians were blinded to the results of other examinations to ensure unbiased assessment.

Main Results:

  • Pocket-sized transthoracic echocardiography (pTTE) demonstrated high sensitivity (85.7%) and specificity (97.9%) for VHD screening.
  • All significant VHD cases (mild severity or greater) were identified by pTTE.
  • Agreement between pTTE and sTTE was good for mitral regurgitation (κ=0.71) and excellent for aortic regurgitation (κ=0.97) and aortic stenosis (κ=0.98).

Conclusions:

  • Pocket-sized transthoracic echocardiography (pTTE) is a reliable method for identifying significant VHD.
  • pTTE, when performed by physicians with level III competency, is recommended as a novel screening tool for VHD.
  • The findings support the integration of pTTE into early VHD screening protocols.
Abstract